lupenone has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X; Wang, Y; Wu, H; Xu, F; Yang, Y; Zhang, M | 1 |
| Huang, X; Kong, J; Li, X; Wang, X; Wu, H; Xu, F; Yang, X; Yu, P; Zhang, L; Zhen, C | 1 |
2 other study(ies) available for lupenone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Study on the mechanism of lupenone for treating type 2 diabetes by integrating pharmacological evaluation and network pharmacology.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin; Insulin Resistance; Male; Network Pharmacology; Rats; Rats, Sprague-Dawley; Triterpenes | 2022 |
Lupenone improves type 2 diabetic nephropathy by regulating NF-κB pathway-mediated inflammation and TGF-β1/Smad/CTGF-associated fibrosis.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eosine Yellowish-(YS); Fibrosis; Hematoxylin; Inflammation; Kidney; Mice; NF-kappa B; Proteinuria; Rats; Transforming Growth Factor beta1 | 2023 |